G. Dock, The influence of complicating diseases upon leukaemia

, Am J Med Sci, vol.127, pp.563-92, 1904.

Z. Zygiert, Hodgkin's disease: remissions after measles, Lancet, vol.1, p.593, 1971.

E. F. Wheelock and J. H. Dingle, Observations on the Repeated Administration of Viruses to a Patient with Acute Leukemia

, N Engl J Med, vol.271, pp.645-51, 1964.

E. Kelly and S. J. Russell, History of oncolytic viruses: genesis to genetic engineering, Mol Ther, vol.15, pp.651-660, 2007.

R. H. Andtbacka, H. L. Kaufman, F. Collichio, T. Amatruda, N. Senzer et al., Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma, J Clin Oncol, vol.33, pp.2780-2788, 2015.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-74, 2011.

J. H. Kim, J. Y. Oh, B. H. Park, D. E. Lee, J. S. Kim et al., Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF, Mol Ther, vol.14, pp.361-70, 2006.

L. Fend, C. Remy-ziller, J. Foloppe, J. Kempf, S. Cochin et al.,

, Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment, Oncoimmunology, vol.5, p.1080414, 2016.

M. Aghi, T. Visted, R. A. Depinho, and E. A. Chiocca, Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16, Oncogene, vol.27, pp.4249-54, 2008.

H. Fukuhara, Y. Ino, T. Kuroda, R. L. Martuza, and T. Todo, Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosomemediated system, Cancer Res, vol.65, pp.10663-10671, 2005.

N. Ramesh, Y. Ge, D. L. Ennist, M. Zhu, M. Mina et al., CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor -armed oncolytic adenovirus for the treatment of bladder cancer, Clin Cancer Res, vol.12, pp.305-318, 2006.

T. Ranki, T. Joensuu, E. Jager, J. Karbach, C. Wahle et al., Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization, Oncoimmunology, vol.3, p.958937, 2014.

J. Fueyo, R. Alemany, C. Gomez-manzano, G. N. Fuller, A. Khan et al., Preclinical characterization of the antiglioma activity of a tropism

, J Natl Cancer Inst, vol.95, pp.652-60, 2003.

K. Garber, China approves world's first oncolytic virus therapy for cancer treatment, J Natl Cancer Inst, vol.98, pp.298-300, 2006.

W. M. Schneider, M. D. Chevillotte, and C. M. Rice, Interferon-stimulated genes: a complex web of host defenses, Annu Rev Immunol, vol.32, pp.513-558, 2014.

I. Canadas, R. Thummalapalli, J. W. Kim, S. Kitajima, R. W. Jenkins et al., Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses, Nat Med, vol.24, pp.1143-50, 2018.

A. Panda, A. A. De-cubas, M. Stein, G. Riedlinger, J. Kra et al., Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma, JCI Insight, vol.23, p.3, 2018.

G. N. Barber, STING : infection, inflammation and cancer, Nat Rev Immunol, vol.15, pp.760-70, 2015.

C. Achard, N. Boisgerault, T. Delaunay, D. Roulois, S. Nedellec et al., Sensitivity of pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response, Oncotarget, vol.6, pp.44892-904, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01285131

B. He, M. Gross, and B. Roizman, The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNAactivated protein kinase, Proc Natl Acad Sci, vol.94, pp.843-851, 1997.

B. L. Liu, M. Robinson, Z. Q. Han, R. H. Branston, C. English et al.,

, deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties, ICP34.5, vol.10, pp.292-303, 2003.

C. Comins, L. Heinemann, K. Harrington, A. Melcher, D. Bono et al., Reovirus: viral therapy for cancer "as nature intended, Clin Oncol (R Coll Radiol), vol.20, pp.548-54, 2008.

F. F. Lang, C. Conrad, C. Gomez-manzano, W. Yung, R. Sawaya et al., Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma, J Clin Oncol, vol.36, pp.1419-1446, 2018.

E. Ylosmaki, T. Hakkarainen, A. Hemminki, T. Visakorpi, R. Andino et al., Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA, J Virol, vol.82, pp.11009-11024, 2008.

J. M. Burke, D. L. Lamm, M. V. Meng, J. J. Nemunaitis, J. J. Stephenson et al., A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer, J Urol, vol.188, pp.2391-2398, 2012.

S. K. Golombek, J. N. May, B. Theek, L. Appold, N. Drude et al., Tumor targeting via EPR: Strategies to enhance patient responses

, Adv Drug Deliv Rev, vol.130, pp.17-38, 2018.

H. L. Kaufman, F. J. Kohlhapp, and A. Zloza, Oncolytic viruses: a new class of immunotherapy drugs, Nat Rev Drug Discov, vol.14, pp.642-62, 2015.

W. Hou, P. Sampath, J. J. Rojas, and S. H. Thorne, Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy, Cancer cell, vol.30, pp.108-127, 2016.

T. T. Huang, S. Parab, R. Burnett, O. Diago, D. Ostertag et al., Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model, Hum Gene Ther, vol.26, pp.82-93, 2015.

S. J. Russell, M. J. Federspiel, K. W. Peng, C. Tong, D. Dingli et al., Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy, Mayo Clin Proc, vol.89, pp.926-959, 2014.

S. Gujar, J. G. Pol, Y. Kim, P. W. Lee, and G. Kroemer, Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies, Trends Immunol, vol.39, pp.209-230, 2018.

A. Iwasaki, A virological view of innate immune recognition, Annu Rev Microbiol, vol.66, pp.177-96, 2012.

E. Venereau, C. Ceriotti, and M. E. Bianchi, DAMPs from Cell Death to New Life, Front Immunol, vol.6, p.422, 2015.

A. Gauvrit, S. Brandler, C. Sapede-peroz, N. Boisgerault, F. Tangy et al., Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response, Cancer Res, vol.68, pp.4882-92, 2008.
URL : https://hal.archives-ouvertes.fr/pasteur-00330770

J. B. Guillerme, N. Boisgerault, D. Roulois, J. Menager, and C. Combredet,

F. Tangy, Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells

, Clin Cancer Res, vol.19, pp.1147-58, 2013.

T. Delaunay, M. Violland, N. Boisgerault, B. Dréno, N. Labarrière et al., Oncolytic viruses sensitize tumor cells for NYESO-1 tumor antigen recognition by CD4+ effector T cells, Oncoimmunology, vol.7, p.1407897, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01644345

C. Achard, A. Surendran, M. E. Wedge, G. Ungerechts, J. Bell et al., Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy, EBioMedicine, vol.31, pp.17-24, 2018.

L. Fend, T. Yamazaki, C. Remy, C. Fahrner, M. Gantzer et al., Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFNalpha Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy, Cancer Res, vol.77, pp.4146-57, 2017.

J. J. Rojas, P. Sampath, W. Hou, and S. H. Thorne, Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy, Clin Cancer Res, vol.21, pp.5543-51, 2015.

C. E. Engeland, C. Grossardt, R. Veinalde, S. Bossow, D. Lutz et al., CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy, Mol Ther, vol.22, pp.1949-59, 2014.

Y. Gao, P. Whitaker-dowling, J. A. Griffin, M. A. Barmada, and I. Bergman,

, Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors

, Cancer Gene Ther, vol.16, pp.44-52, 2009.

W. Shen, M. M. Patnaik, A. Ruiz, S. J. Russell, and K. W. Peng, Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia, Blood, vol.127, pp.1449-58, 2016.

K. Rajani, C. Parrish, T. Kottke, J. Thompson, S. Zaidi et al., Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses, Mol Ther, vol.24, pp.166-74, 2016.

D. Zamarin, R. B. Holmgaard, S. K. Subudhi, J. S. Park, M. Mansour et al., Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy, Sci Transl Med, vol.6, pp.226-258, 2014.

I. Puzanov, M. M. Milhem, D. Minor, O. Hamid, A. Li et al., Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma, J Clin Oncol, vol.34, pp.2619-2645, 2016.

A. Ribas, R. Dummer, I. Puzanov, A. Vanderwalde, R. Andtbacka et al., Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, Cell, vol.170, pp.1109-1128, 2017.

J. F. Fonteneau, C. Achard, C. Zaupa, J. Foloppe, and P. Erbs, Oncolytic immunotherapy: the new clinical outbreak, Oncoimmunology, vol.5, p.1066961, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01285132

P. Alberts, A. Tilgase, A. Rasa, K. Bandere, and D. Venskus, The advent of oncolytic virotherapy in oncology: The Rigvir(R) story, Eur J Pharmacol, vol.837, pp.117-143, 2018.

T. C. Liu, T. H. Hwang, J. C. Bell, and D. H. Kirn, Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a highvalue iterative loop, Mol Ther, vol.16, pp.1006-1014, 2008.

J. Pol, A. Buque, F. Aranda, N. Bloy, I. Cremer et al., Trial Watch-Oncolytic viruses and cancer therapy, Oncoimmunology, vol.5, p.1117740, 2016.

J. Pol, S. Levesque, S. T. Workenhe, S. Gujar, L. Boeuf et al., Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors, Oncoimmunology, vol.7, p.1503032, 2018.

. L'immuno-virothérapie-oncolytique, une stratégie émergente de traitement du cancer Oncolytic Immunovirotherapy: An Emerging Strategy for Cancer Treatment

J. Chesney, I. Puzanov, F. Collichio, P. Singh, M. M. Milhem et al., Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma, J Clin Oncol, vol.36, pp.1658-67, 2018.

C. J. Larocca and S. G. Warner, Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials, Clin Transl Med, vol.7, p.35, 2018.

M. Senior, Checkpoint inhibitors go viral, Nat Biotechnol, vol.37, pp.12-19, 2019.
DOI : 10.1038/nbt.4327

P. K. Bommareddy, M. Shettigar, and H. L. Kaufman, Integrating oncolytic viruses in combination cancer immunotherapy, Nat Rev Immunol, vol.18, pp.498-513, 2018.

I. Melero, D. M. Berman, M. A. Aznar, A. J. Korman, P. Gracia et al., Evolving synergistic combinations of targeted immunotherapies to combat cancer, Nat Rev Cancer, vol.15, pp.457-72, 2015.

A. Ajina and J. Maher, Prospects for combined use of oncolytic viruses and CAR T-cells, J Immunother Cancer, vol.5, p.90, 2017.

J. Burke, J. Nieva, M. J. Borad, and C. J. Breitbach, Oncolytic viruses: perspectives on clinical development, Curr Opin Virol, vol.13, pp.55-60, 2015.
DOI : 10.1016/j.coviro.2015.03.020

K. Fisher, Striking out at disseminated metastases: the systemic delivery of oncolytic viruses, Curr Opin Mol Ther, vol.8, pp.301-314, 2006.

A. Anthoney, A. Samson, E. West, S. J. Turnbull, K. Scott et al., Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity, J Clin Oncol, vol.36, p.3092, 2018.

C. J. Breitbach, J. Burke, D. Jonker, J. Stephenson, A. R. Haas et al., Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans, Nature, vol.477, pp.99-102, 2011.

R. A. Berkeley, L. P. Steele, A. A. Mulder, D. Van-den-wollenberg, T. J. Kottke et al., Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy, Cancer Immunol Res, vol.6, pp.1161-73, 2018.

L. A. Rojas, R. Moreno, H. Calderon, and R. Alemany, Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction, Cancer Gene Ther, vol.23, pp.411-415, 2016.

R. Myers, C. Coviello, P. Erbs, J. Foloppe, C. Rowe et al., Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus

, Mol Ther, vol.24, pp.1627-1660, 2016.

C. G. Lemay, B. A. Keller, R. E. Edge, M. Abei, and J. C. Bell, Oncolytic Viruses: The Best is Yet to Come, Curr Cancer Drug Targets, vol.18, pp.109-132, 2018.

K. Twumasi-boateng, J. L. Pettigrew, Y. Kwok, J. C. Bell, and B. H. Nelson, Oncolytic viruses as engineering platforms for combination immunotherapy, Nat Rev Cancer, vol.18, pp.419-451, 2018.